Milanović Maja, Milošević Nataša, Ružić Maja, Abenavoli Ludovico, Milić Nataša
Department of Pharmacy, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21000 Novi Sad, Serbia.
Faculty of Medicine, University of Novi Sad, Clinic for Infectious Diseases, University Clinical Centre of Vojvodina, Hajduk Veljkova 1, 21000 Novi Sad, Serbia.
Metabolites. 2025 Aug 1;15(8):516. doi: 10.3390/metabo15080516.
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is a prevalent, multisystem disease affecting approximately 30% of adults worldwide. Obesity, along with dyslipidemia, type 2 diabetes mellitus, and hypertension, are closely intertwined with MASLD. In people with obesity, MASLD prevalence is estimated to be about 75%. Despite various approaches to MASLD treatment, dietary changes remain the most accessible and safe interventions in MASLD, especially in obese and overweight patients. Whey proteins are rich in bioactive compounds, essential amino acids with antioxidant properties, offering potential benefits for MASLD prevention and management. This state-of-the-art review summarizes whey protein impacts on a spectrum of MASLD-related manifestations, such as obesity, impaired glucose and lipid metabolism, hypertension, liver injury, oxidative stress, and inflammation. The results obtained in clinical environments, with a focus on meta-analysis, propose whey protein supplementation as a promising strategy aimed at managing multifaced MASLD disorders. Well-designed cohort studies are needed for validation of the efficacy and long-term safety of whey proteins in MASLD patients.
代谢功能障碍相关脂肪性肝病（MASLD），以前称为非酒精性脂肪性肝病（NAFLD），是一种普遍的多系统疾病，影响着全球约30%的成年人。肥胖与血脂异常、2型糖尿病和高血压一起，与MASLD密切相关。在肥胖人群中，MASLD的患病率估计约为75%。尽管有多种治疗MASLD的方法，但饮食改变仍然是MASLD中最容易获得且安全的干预措施，尤其是对于肥胖和超重患者。乳清蛋白富含生物活性化合物、具有抗氧化特性的必需氨基酸，对MASLD的预防和管理具有潜在益处。这篇最新综述总结了乳清蛋白对一系列与MASLD相关表现的影响，如肥胖、糖脂代谢受损、高血压、肝损伤、氧化应激和炎症。在临床环境中获得的结果，重点是荟萃分析，提出补充乳清蛋白是一种有前景的策略，旨在管理多方面的MASLD疾病。需要设计良好的队列研究来验证乳清蛋白在MASLD患者中的疗效和长期安全性。
